In person As in the previous years ZoBio attended the European Conference on Magnetic Resonance, which took place in Göteborg, Sweden. Stephan Theisgen presented a poster demonstrating how strategically integrating solution-state NMR into commercial drug discovery programs provides critical structural insights across the early preclinical pipeline. The poster highlighted how NMR complements biochemical assays, biophysical…

Molecular glues are rapidly emerging as a transformative modality in drug discovery, enabling novel mechanisms to modulate protein function through stabilization of protein–protein interactions. Yet discovering synthetic molecular glues de novo remains a major challenge, particularly due to the need to identify compounds that both engage a target and promote cooperative ternary complex formation.

ZoBio is excited to attend TFMED 2026, a four-day transdisciplinary conference dedicated to next-generation therapeutic modalities, including molecular glues, PROTACs, nucleic acid-based therapies, and cell-based approaches.

The meeting brings together researchers, clinicians, and industry experts, offering in-depth scientific sessions, direct interaction with leading specialists, and valuable opportunities for networking and collaboration, with a strong focus on early-career scientists.